NCT06008353 - A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in Brazil | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions

Extensive-stage Small-cell Lung Cancer

Interventions

OTHER

Observational study

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Trial Locations (5)

ÉTICA Clínica AMO - Assistência Multidisciplinar em Oncologia, Salvador

Oncologia D'Or Unidade Esperança Pernambuco, Recife

Instituto D'Or de Pesquisa e Ensino RJ, Rio de Janeiro

BP - A Beneficência Portuguesa de São Paulo, São Paulo

A.C. Camargo Cancer Center, São Paulo